By specifically targeting MEG3, the therapeutic potential is presented for the restoration of normal bone metabolism, the modulation of bone-related signaling pathways, and the development of novel treatments for a variety of bone illnesses, such as osteoporosis and bone cancer. The gene discussed is MEG3; the disease is bone cancer.